Genmab to Highlight Epcoritamab-bysp Development at 2024 ASH Annual Meeting

Genmab A/S (Nasdaq: GMAB) today announced that over 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a subcutaneously administered T-cell engaging bispecific antibody, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place December 7-10, 2024,…

Read MoreGenmab to Highlight Epcoritamab-bysp Development at 2024 ASH Annual Meeting

Immunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment

Immunis, Inc., a clinical-stage biotechnology company focused on developing innovative secretomes for age-related diseases and immune dysfunction, has launched non-terminal safety studies for canine muscle atrophy in collaboration with VetBio Partners, LLC. This follows the successful preclinical results of Immunis’…

Read MoreImmunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment

Inquis Medical Secures $40M in Series B Funding to Advance Aventus Thrombectomy System

Inquis Medical, an innovator in advanced thrombectomy systems, today announced the successful closure of its oversubscribed $40 million Series B financing round. The round was led by Marshall Wace, a globally renowned investment firm, with strong support from existing investors…

Read MoreInquis Medical Secures $40M in Series B Funding to Advance Aventus Thrombectomy System